Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel pharmacogenetic markers for treatment outcome in azathioprine‐treated inflammatory bowel disease

3 Jun 2009

Abstract excerpt

BACKGROUND: Azathioprine (AZA) pharmacogenetics are complex and much studied. Genetic polymorphism in TPMT is known to influence treatment outcome. Xanthine oxidase/dehydrogenase (XDH) and aldehyde oxidase (AO) compete with TPMT to inactivate AZA. AIM: To assess whether genetic polymorphism in AOX1, XDH and MOCOS (the product of which activates the essential cofactor for AO and XDH) is associated with AZA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Celiac Disease Research and Management
Share to Pharmacogenetics and Drug Metabolism

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19500084
DOI: 10.1111/j.1365-2036.2009.04057.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel pharmacogenetic markers for treatment outcome in azathioprine‐treated inflammatory bowel diseasePMID 19500084Read ↗

AOX1 and XDH Enzymes Genotyping and its Effect on Clinical Response to Azathioprine in Inflammatory Bowel Disease Patients Among Jordanian Population.Semantic proximity Read ↗

Polymorphism of genes involved in purine metabolism (XDH, AOX1, MOCOS) in kidney transplant recipients receiving azathioprine.Semantic proximity Read ↗

Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease.Semantic proximity Read ↗

HLA-DQA1-HLA-DRB1 polymorphism is a major predictor of azathioprine-induced pancreatitis in patients with inflammatory bowel disease.Semantic proximity Read ↗

A pharmacogenetics study of TPMT and ITPA genes detects a relationship with side effects and clinical response in patients with inflammatory bowel disease receiving Azathioprine.Semantic proximity Read ↗

Pharmacogenetics of Thiopurines in Inflammatory Bowel DiseaseSemantic proximity Read ↗

New genetic biomarkers predicting azathioprine blood concentrations in combination therapy with 5-aminosalicylic acid.Semantic proximity Read ↗

Pharmacogenetics of inflammatory bowel disease.Semantic proximity Read ↗

Revisiting the Role of Thiopurines in Inflammatory Bowel Disease Through Pharmacogenomics and Use of Novel Methods for Therapeutic Drug MonitoringSemantic proximity Read ↗

Thiopurine Drugs in the Treatment of Ulcerative Colitis: Identification of a Novel Deleterious Mutation in TPMT.Semantic proximity Read ↗

Effective long-term solution to therapeutic remission in Inflammatory Bowel Disease: Role of Azathioprine.Semantic proximity Read ↗

Glutathione-S-transferase genotypes and the adverse effects of azathioprine in young patients with inflammatory bowel disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.